Search details
1.
Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study.
J Immunol
; 2024 May 17.
Article
in English
| MEDLINE | ID: mdl-38758119
2.
Different risk genes contribute to clear cell and non-clear cell renal cell carcinoma in 1532 Japanese patients and 5996 controls.
Hum Mol Genet
; 31(12): 1962-1969, 2022 06 22.
Article
in English
| MEDLINE | ID: mdl-35764097
3.
Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy.
Ann Surg Oncol
; 31(6): 3872-3879, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38353798
4.
The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapy.
Int J Clin Oncol
; 2024 May 26.
Article
in English
| MEDLINE | ID: mdl-38797782
5.
Validation study on the 2 mm diameter cutoff in lymph node-positive cases following radical prostatectomy in accordance with the AJCC/UICC TNM 8th edition: Real-world data analysis from a Japanese cohort.
Int J Urol
; 31(6): 662-669, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38424729
6.
Genetic variations predicting progression with docetaxel and novel androgen-receptor pathway inhibitors.
Cancer Sci
; 114(4): 1625-1634, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-36602227
7.
Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
Prostate
; 83(6): 563-571, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36661102
8.
Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study.
World J Urol
; 41(1): 67-75, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36520204
9.
Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis.
World J Urol
; 41(8): 2051-2062, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-35596809
10.
Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate.
Eur J Clin Pharmacol
; 79(1): 89-98, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36378297
11.
Increasing age predicts adverse pathology including intraductal carcinoma of the prostate and cribriform patterns in deferred radical prostatectomy after upfront active surveillance for Gleason grade group 1 prostate cancer: analysis of prospective observational study cohort.
Jpn J Clin Oncol
; 53(10): 984-990, 2023 Oct 04.
Article
in English
| MEDLINE | ID: mdl-37496400
12.
Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old.
Int J Clin Oncol
; 28(11): 1530-1537, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37552353
13.
Trends in the use of local intervention for metastatic hormone-naïve prostate cancer: A multicenter retrospective study.
Int J Urol
; 30(11): 969-976, 2023 11.
Article
in English
| MEDLINE | ID: mdl-37403901
14.
The efficacy of sequential therapy with docetaxel and cabazitaxel for castration-resistant prostate cancer: A retrospective multi-institutional study in Japan.
Int J Urol
; 30(2): 227-234, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36375045
15.
Machine learning diagnosis by immunoglobulin N-glycan signatures for precision diagnosis of urological diseases.
Cancer Sci
; 113(7): 2434-2445, 2022 Jul.
Article
in English
| MEDLINE | ID: mdl-35524940
16.
Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab.
Cancer Sci
; 113(12): 4059-4069, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-35848083
17.
Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancer.
Cancer Sci
; 113(7): 2386-2396, 2022 Jul.
Article
in English
| MEDLINE | ID: mdl-35485635
18.
Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
Prostate
; 82(13): 1304-1312, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35747992
19.
Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.
Prostate
; 82(14): 1322-1330, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35767376
20.
Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer.
Br J Cancer
; 127(9): 1680-1690, 2022 11.
Article
in English
| MEDLINE | ID: mdl-35986085